Innovent Presents P-I Clinical Trial Results of IBI322 for the Treatment of Classic Hodgkin Lymphoma at EHA 2023
Shots:
- The P-I trial results based on a dose-expansion cohort evaluating IBI322 (45mg/kg, IV, q2w) in patients with anti-PD-(L)1-resistant classic Hodgkin lymphoma
- The results showed ORR (47.8%) & DCR (91.3%) among the 23 patients while ORR (57.1%) and 3 patients achieved CR among the 7 patients with primary resistance, the incidence of TRAE (91.7%), the incidence of grade ≥3 TRAE (41.7%) with the most common ≥grade 3 TRAE (>5%) associated with decreased lymphocyte count (29.2%)
- No TRAE leading to permanent treatment discontinuation or death. IBI322 (anti-human CD47/PD-L1 bispecific Ab) also showed a promising anti-tumor efficacy with a manageable safety profile
Ref: PRNewswire | Image: Innovent
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
